Astrana Health Earnings Call Highlights Growth and Deleveraging

Astrana Health (ASTH) reported Q3 revenue of $1.02B (+7% YoY) and adjusted EBITDA of $77.2M (+13% YoY). The company highlighted organic growth, debt reduction, and favorable Medicare trends. Management maintained full-year guidance, expecting revenue of $3.9B-$4B and adjusted EBITDA of $261M-$274M. Challenges include Medicaid pressure and seasonality.

Original reporting
Published Nov 7, 2026, 12:21 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 7, 2026, 4:24 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ASTH
Bullish
high confidence
Mentioned
$ASTH
Relevance
8/10
AlphAI data visualization · based on tipranks.com
Decision brief

The 30-second read

$ASTHBullishHigh
01

Why it matters

The earnings beat and leverage reduction improve financial health, but ongoing Medicaid challenges and a cybersecurity probe could temper gains.

02

Market read

Strong Q3 performance may drive short‑term price appreciation and influence peer valuations in the health‑care services space.

03

What to watch

Cybersecurity investigation and Medicaid attrition risk may limit upside.

Relevance 8/10Novelty 8/10Timing: after-hours reaction today

Background

Astrana Health is a Medicare Advantage and health‑care services provider that recently integrated Prospect and expanded full‑risk arrangements.

Company-level read

Ticker impact

$ASTHBullishHigh confidence
Context

Q3 earnings call disclosed record $1.02B revenue, $77.2M adjusted EBITDA, $0.71 EPS and raised full-year guidance.

Expected impact

upward pressure as market prices in better-than-expected results and leverage reduction

Evidence & confidence

Revenue and EBITDA beat expectations, debt repayment improves balance sheet, and guidance remains robust.

Market effects

Strengthens outlook for health‑care services and Medicare Advantage providers.

Positive for U.S. health‑care stocks, especially mid‑cap insurers.

Limited to U.S. health‑care sector; no broader macro impact.

Counterpoint

If Medicaid cost pressures intensify, earnings could be pressured despite current beat.

Key entities

  • Astrana Health Inc.

    U.S. health‑care services firm reporting Q3 results.

Related articles

$ASTHMed

Astrana Health 3Q 2026: Revenue $1.02B, EPS $0.26 — 10-Q Summary

Astrana Health reported 3Q 2026 revenue of $1.02B, up 7% YoY, and net income of $13.0M, compared to $373K last year. Growth was driven by 9% increase in capitation revenue. Care Partners saw 8% revenue growth and 94% operating income rise, while Care Delivery revenue increased 5% but operating loss widened. Care Enablement revenue rose 5% with 4% higher operating income. Astrana managed 29 IPAs and 1.5M patients as of September 30, 2026.

$ASTHMed

Astrana Health Inc (ASTH) (Q3 2026) Earnings Call Highlights: Record Revenue and EBITDA

Astrana Health Inc (ASTH) reported Q3 2026 earnings, highlighting record revenue and EBITDA growth. CEO Brandon Sim discussed Medicaid membership attrition, Medicare Advantage dynamics, and care enablement business momentum. The company expects mid-teens EBITDA growth despite Medicaid headwinds. A cybersecurity incident is under investigation, and a new 'premiums at risk' disclosure was introduced for ACO business transparency.

$ASTHHighAI 8/10

Astrana Health (ASTH) Q3 2026 Earnings Call Transcript

Astrana Health (ASTH) reported Q3 2026 revenue of $1.02B (+7% YoY) and adjusted EBITDA of $77.2M (+13% YoY). Membership grew to 1.5M, with Medicare Advantage increasing organically. The company completed acquisitions and partnerships, expanding its presence. Medical cost trends were slightly better than expected, with Texas operations performing ahead of plan. Free cash flow reached $105M, and net leverage was reduced to 2.2x.

$ASTHMed

Astrana Health Q3 Earnings Call Highlights

Astrana Health reported 1.5 million members under management, with Medicare Advantage growth offsetting Medicaid attrition. The company expects Medicaid membership to decline 10-15% in 2027, impacting adjusted EBITDA. Medical cost trends were slightly better than expected, with Medicare Advantage margins stable. Astrana plans 82% of capitation revenue from full-risk arrangements by 2026 and completed acquisitions and partnerships.